Vernalis plc (LON:VER) has been given a consensus rating of “Hold” by the six research firms that are currently covering the firm, Marketbeat reports. Four research analysts have rated the stock with a hold recommendation and one has assigned a buy recommendation to the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is GBX 46.80 ($0.59).

A number of brokerages recently weighed in on VER. Panmure Gordon lowered shares of Vernalis plc to a “hold” rating and set a GBX 65 ($0.82) target price for the company. in a research report on Friday, April 21st. Stifel Nicolaus dropped their target price on shares of Vernalis plc from GBX 29 ($0.37) to GBX 24 ($0.30) and set a “hold” rating for the company in a research report on Friday, April 21st. Numis Securities Ltd began coverage on shares of Vernalis plc in a research report on Tuesday, April 4th. They set an “add” rating and a GBX 29 ($0.37) target price for the company. Finally, N+1 Singer restated a “hold” rating and set a GBX 28 ($0.35) target price on shares of Vernalis plc in a research report on Friday, April 21st.

Vernalis plc (LON:VER) traded up 0.685% during mid-day trading on Friday, hitting GBX 18.375. 47,922 shares of the stock traded hands. The company’s 50 day moving average is GBX 18.26 and its 200 day moving average is GBX 26.49. The company’s market cap is GBX 96.72 million. Vernalis plc has a 12 month low of GBX 16.00 and a 12 month high of GBX 49.75.

WARNING: This story was reported by American Banking News and is owned by of American Banking News. If you are reading this story on another website, it was copied illegally and reposted in violation of US and international copyright & trademark legislation. The original version of this story can be accessed at https://www.americanbankingnews.com/2017/06/16/vernalis-plc-ver-given-consensus-recommendation-of-hold-by-analysts.html.

About Vernalis plc

Vernalis plc is a commercial-stage pharmaceutical company. The Company is engaged in the research, development and commercialization of pharmaceutical products. The Company operates through two segments: Commercial, which covers all areas relating to the commercial sale of pharmaceutical products, the manufacture and distribution directly related to that activity, and Research and Development, which includes all activities related to the research and development of pharmaceutical products for a range of medical disorders.

Receive News & Ratings for Vernalis plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vernalis plc and related companies with MarketBeat.com's FREE daily email newsletter.